PAVmed Inc. (NASDAQ:PAVM – Get Free Report)’s share price passed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $3.95 and traded as low as $2.04. PAVmed shares last traded at $2.05, with a volume of 14,828 shares.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings lowered PAVmed from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $56.00.
View Our Latest Stock Analysis on PAVmed
PAVmed Stock Performance
The company has a debt-to-equity ratio of 0.98, a current ratio of 1.19 and a quick ratio of 1.19. The stock has a fifty day simple moving average of $3.95 and a two-hundred day simple moving average of $5.49. The firm has a market capitalization of $16.40 million, a P/E ratio of -0.13 and a beta of 0.69.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in PAVmed stock. Two Seas Capital LP bought a new position in shares of PAVmed Inc. (NASDAQ:PAVM – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 461,539 shares of the company’s stock, valued at approximately $2,742,000. Two Seas Capital LP owned approximately 46.15% of PAVmed as of its most recent SEC filing. 19.93% of the stock is currently owned by hedge funds and other institutional investors.
About PAVmed
PAVmed Inc is a medical device and diagnostics company focused on developing and commercializing technologies intended to improve the diagnosis and treatment of serious medical conditions. The company operates through subsidiaries and strategic business units that address areas including cancer detection, remote patient monitoring, vascular access and minimally invasive procedures.
One of PAVmed’s primary businesses is its majority-owned subsidiary Lucid Diagnostics, which developed the EsoGuard DNA test and EsoCheck cell-collection device.
Recommended Stories
- Five stocks we like better than PAVmed
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.
